CNSX:IME

Stock Analysis Report

Executive Summary

Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Imagin Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IME

-2.5%

CA Medical Equipment

0.3%

CA Market


1 Year Return

-64.3%

IME

-15.9%

CA Medical Equipment

0.1%

CA Market

Return vs Industry: IME underperformed the Canadian Medical Equipment industry which returned -15.9% over the past year.

Return vs Market: IME underperformed the Canadian Market which returned 0.1% over the past year.


Shareholder returns

IMEIndustryMarket
7 Day0%-2.5%0.3%
30 Day-16.7%-14.4%-2.5%
90 Day-23.1%-15.4%-1.4%
1 Year-64.3%-64.3%-15.9%-15.9%3.6%0.1%
3 Year-47.4%-47.4%-50.3%-50.3%14.3%4.1%
5 Yearn/a-86.7%-86.7%25.0%6.9%

Price Volatility Vs. Market

How volatile is Imagin Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Imagin Medical undervalued compared to its fair value and its price relative to the market?

2.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate IME's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IME's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IME is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IME is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate IME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IME is good value based on its PB Ratio (2x) compared to the CA Medical Equipment industry average (5.6x).


Next Steps

Future Growth

How is Imagin Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

56.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagin Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Imagin Medical performed over the past 5 years?

-50.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IME is unprofitable, and losses have increased over the past 5 years at a rate of -50.8% per year.

Accelerating Growth: Unable to compare IME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (27.4%).


Return on Equity

High ROE: IME has a negative Return on Equity (-156.15%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IME is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IME is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Imagin Medical's financial position?


Financial Position Analysis

Short Term Liabilities: IME's short term assets (CA$3.5M) exceeds its short term liabilities (CA$254.9K)

Long Term Liabilities: IME has no long term liabilities


Debt to Equity History and Analysis

Debt Level: IME is debt free.

Reducing Debt: IME had no debt 5 years ago.


Balance Sheet

Inventory Level: IME has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IME's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IME has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IME has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47.4% each year


Next Steps

Dividend

What is Imagin Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IME's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IME's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Imagin Medical's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average board tenure


CEO

Jim Hutchens 0

3.7yrs

Tenure

CA$1,643,857

Compensation

Mr. Edward James Hutchens, also known as Jim, is the Co-founder and Managing Director of Origin Partners. Mr. Hutchens has been Chief Executive Officer and President of Imagin Medical Inc. since February 2 ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jim's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.0yrs

Average Tenure

Experienced Board: IME's board of directors are considered experienced (3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$6,69618 Jun 19
Christopher Bleck
EntityIndividual
Role
Member of the Board of Directors
Director
Shares83,472
Max PriceCA$0.08
BuyCA$8,25012 Jun 19
Edward Hutchens
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares100,000
Max PriceCA$0.085
BuyCA$6,33612 Jun 19
John Vacha
EntityIndividual
Role
Member of the Board of Directors
CFO, Corporate Secretary & Director
Shares72,000
Max PriceCA$0.09
BuyCA$7,39412 Jun 19
Kenneth Daignault
EntityIndividual
Role
Member of the Board of Directors
Director
Shares82,236
Max PriceCA$0.09

Ownership Breakdown


Management Team

  • Jim Hutchens

    CEO, President & Director

    • Tenure: 3.7yrs
    • Compensation: CA$1.64m
  • John Vacha

    CFO, Corporate Secretary & Director

    • Tenure: 1.8yrs
    • Compensation: CA$260.11k
  • Thom McMahon

    Director of Sales

    • Tenure: 0yrs

Board Members

  • Chris Bleck (62yo)

    Director

    • Tenure: 1yrs
  • Jim Hutchens

    CEO, President & Director

    • Tenure: 3.7yrs
    • Compensation: CA$1.64m
  • John Vacha

    CFO, Corporate Secretary & Director

    • Tenure: 1.8yrs
    • Compensation: CA$260.11k
  • Ralph de Vere White

    Chairman of Scientific Medical Advisory Board

    • Tenure: 3.5yrs
  • Edward Messing

    Member of Scientific Medical Advisory Board

    • Tenure: 3.1yrs
  • Ashish Kamat

    Member of Scientific Advisory Board

    • Tenure: 0.5yrs
  • Robin Atlas (67yo)

    Chairperson

    • Tenure: 0yrs
    • Compensation: CA$6.00k
  • Ken Daignault

    Director

    • Tenure: 3.1yrs
    • Compensation: CA$38.01k
  • Liam Hurley

    Member of Scientific Medical Advisory Board

    • Tenure: 3yrs
  • Roger Buckley

    Member of Scientific Medical Advisory Board

    • Tenure: 2.9yrs

Company Information

Imagin Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Imagin Medical Inc.
  • Ticker: IME
  • Exchange: CNSX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$6.953m
  • Shares outstanding: 139.06m
  • Website: https://imaginmedical.com

Location

  • Imagin Medical Inc.
  • 890 West Pender Street
  • Suite 600
  • Vancouver
  • British Columbia
  • V6C 1L9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DPD2DB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2016
IMEX.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2016
IMECNSX (Canadian National Stock Exchange)YesCommon SharesCACADFeb 2016

Biography

Imagin Medical Inc. engages in developing imaging solutions for the early detection of cancer through the use of endoscopes. Its ultrasensitive imaging technology is based on improved optical designs and a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:26
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.